ReviewToxins2019
Public Health Risks Associated with Tetrodotoxin and Its Analogues in European Waters: Recent Advances after The EFSA Scientific Opinion.
Review in Toxins, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Pooled it
- Tetrodotoxin (TTX): What do we currently know? The state of the art.Archives of toxicology · 2026Review
- Optimization and Intra-Laboratory Validation of the Neuro-2a Assay for Tetrodotoxin Detection in Mussels.Marine drugs · 2026Article
- Review
- Potential Increase in Known and Emerging Biotoxins in Marine Ecosystem Due to Climate Change and Subsequent Health Issues.Foods (Basel, Switzerland) · 2026Review
- Toxicity Profile of the Oceanic PufferfishMarine drugs · 2026Article
- Article
- Searching for Paralytic Toxin, Tetrodotoxin, in Swedish Bivalve Shellfish.Marine drugs · 2025Article
- Investigating Non-Native Ribbon WormMarine drugs · 2024Article
- Tetrodotoxin and the state-of-the-art progress of its associated analytical methods.Frontiers in microbiology · 2024Review
- Article
- First Toxicological Analysis of the PufferfishAnimals : an open access journal from MDPI · 2023Article
- New Vectors of TTX Analogues in the North Atlantic Coast: The Edible CrabsMarine drugs · 2023Article
- First Report of Two Gymnodimines and Two Tetrodotoxin Analogues in Invertebrates from the North Atlantic Coast of Spain.Marine drugs · 2023Article
- Interlaboratory Evaluation of Multiple LC-MS/MS Methods and a Commercial ELISA Method for Determination of Tetrodotoxin in Oysters and Mussels.Journal of AOAC International · 2023Article
- An Updated Review of Tetrodotoxin and Its Peculiarities.Marine drugs · 2022Review
- Hybrid Antibody-Aptamer Assay for Detection of Tetrodotoxin in Pufferfish.Analytical chemistry · 2021Article
- Article
- Distribution of Tetrodotoxin in Pacific Oysters (Marine drugs · 2021Article
- A Microencapsulation Method for Delivering Tetrodotoxin to Bivalves to Investigate Uptake and Accumulation.Marine drugs · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tetrodotoxin (TTX) and its analogues are naturally occurring toxins responsible worldwide for human intoxication cases and fatalities, mainly associated with pufferfish consumption. In the last decade, TTXs were detected in marine bivalves and gastropods from European waters. As TTXs are not regulated or monitored at EU level, their unexpected occurrence in shellfish raised concerns as a food safety hazard and revealed the necessity of a thorough assessment on the public health risks associated with their presence. For this reason, the European Food Safety Authority (EFSA) was requested by the European Commission to provide a scientific opinion, finally adopted in March 2017, according to which a provisional concentration below 44 μg TTX equivalents/kg shellfish meat, based on a large portion size of 400 g, was considered not to result in adverse effects in humans. The EFSA expert panel, however, recognized a number of shortcomings and uncertainties related to the unavailability of sufficient scientific data and provided relevant recommendations for future research to overcome these data gaps identified in order to further refine the risk assessment on TTXs. The present review aims to summarize the knowledge obtained towards addressing these recommendations in the two years following publication of the EFSA opinion, at the same time highlighting the points requiring further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.